COMMUNIQUÉS West-GlobeNewswire

Verona Pharma plc : Holding(s) in Company

06/06/2017 - 12:54

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting [...]

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

06/06/2017 - 11:00

Heidelberg, Germany, June 6, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Company [...]

Helsinn: First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Dr Sarah A Buckley

06/06/2017 - 10:30

First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington Lugano, Switzerland, [...]

Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for Prediction of Acute Kidney Injury Cleared, Available in Europe

06/06/2017 - 08:30

New test expands Ortho's VITROS(R) menu RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the [...]

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

06/06/2017 - 07:15

Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel [...]

Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

06/06/2017 - 07:15

Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna [...]

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

06/06/2017 - 07:01

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that [...]

VALNEVA Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York

06/06/2017 - 07:00

Valneva Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York Lyon (France), 6 juin 2017 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la production et [...]

VALNEVA to Present at Jefferies 2017 Global Healthcare Conference in New York

06/06/2017 - 07:00

Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York Lyon (France), June 06, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on [...]

Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London

06/06/2017 - 07:00

Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal agenda for its Capital [...]

Addex Annual General Meeting Scheduled for 22 June 2017

06/06/2017 - 07:00

Geneva, Switzerland 6 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 22 June 2017, at 11:00am at the Campus Biotech, Chemin des Mines 9, 1202 [...]

Michael Phelps, athlète champion du monde et défenseur de la santé mentale, nommé au Conseil d'administration de Medibio

06/06/2017 - 06:34

SYDNEY, Australie, le 6 juin 2017 (GLOBE NEWSWIRE) - Medibio Limited (ASX : MEB) (MEB ou la Société), société de technologie médicale cotée sur ASX qui a développé un test objectif efficace pour aider au diagnostic de [...]

Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer

05/06/2017 - 22:05

Phase I/II study to evaluate Mekinist ® (trametinib) in combination with Opdivo ® (nivolumab) and Opdivo + Yervoy ® (ipilimumab) Collaboration expands upon existing clinical investigation of Opdivo combination with [...]

NANOBIOTIX : données prometteuses de l'essai de phase I/II dans les cancers de la Tête et du Cou avec NBTXR3 ; présentées au Congres Annuel de L'ASCO

05/06/2017 - 18:00

NANOBIOTIX : DONNEES PROMETTEUSES DE l'ESSAI DE PHASE I/II DANS LES CANCERS DE LA TETE ET DU COU AVEC NBTXR3 ; PRESENTEES AU CONGRES ANNUEL DE L'ASCO Très bon profil de sécurité sans aucun effet indésirable chez des [...]

NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting

05/06/2017 - 18:00

NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING Very good safety profile with no AEs and SAEs in stage III/IV in [...]

Bio-on presents a revolutionary new technology to eliminate oil pollution in the sea within 3 weeks

05/06/2017 - 15:09

Bio-on presents a revolutionary new technology to eliminate oil pollution in the sea within 3 weeks. New Minerv Biorecovery technology, patented worldwide by Bio-on and based on the revolutionary 100% biodegradable [...]

Bio-on présente une nouvelle technologie révolutionnaire pour éliminer en 3 semaines la pollution marine par le pétrole

05/06/2017 - 15:09

Bio-on présente une nouvelle technologie révolutionnaire pour éliminer en 3 semaines la pollution marine par le pétrole. La nouvelle technologie Minerv Biorecovery, brevetée par Bio-on dans le monde entier et s'appuyant [...]

HalioDx : Immunosign® gene signature assesses LTX-315 ability to turn 'cold' tumors 'hot' at ASCO 2017

05/06/2017 - 15:00

Immunosign® gene signature assesses LTX-315 ability to turn 'cold' tumors 'hot' at ASCO 2017 Immune gene expression signature Immmunosign® was applied to a set of pre and post LTX-315 treatment biopsies Immunosign® [...]

HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017

05/06/2017 - 15:00

HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017 For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin [...]